# A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab (Avastin) Plus Platinum And Paclitaxel or With Pemetrexed Plus Platinum in Patients With Non-Squamous Non-Small Cell Lung Cancer

> **NCT01496742** · PHASE2 · COMPLETED · sponsor: **Genentech, Inc.** · enrollment: 259 (actual)

## Conditions studied

- Non-Squamous Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Placebo
- **DRUG:** RO5490258
- **DRUG:** bevacizumab [Avastin]
- **DRUG:** cisplatin/carboplatin
- **DRUG:** paclitaxel
- **DRUG:** pemetrexed

## Key facts

- **NCT ID:** NCT01496742
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-04
- **Primary completion:** 2015-11
- **Final completion:** 2015-11
- **Target enrollment:** 259 (ACTUAL)
- **Last updated:** 2016-09-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01496742

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01496742, "A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab (Avastin) Plus Platinum And Paclitaxel or With Pemetrexed Plus Platinum in Patients With Non-Squamous Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT01496742. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*